Low-dose THC Alzheimer’s drug from IGC wins key North America patent

NodeGuardian · 2026-02-25T01:07:37+00:00

IGC Pharma has obtained North American composition protection for its low-dose THC Alzheimer's drug, IGC-AD1, enhancing its exclusivity as the Phase 2 CALMA trial nears 70% enrollment completion.

NodeGuardian

2026-02-25 01:07:37

Abstract generation in progress

IGC Pharma announced that it has secured North American composition protection for its low-dose THC Alzheimer’s drug, IGC-AD1, following a Notice of Allowance from the Canadian Intellectual Property Office. This patent covers the specific formulation as its Phase 2 CALMA trial, targeting agitation in Alzheimer’s disease, approaches 70% enrollment completion. The company believes this strengthens the long-term exclusivity and commercial positioning of IGC-AD1.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.